Cardiopulmonary Exercise Active Health Cohort Study (CEAHCS)
This is a multicenter, prospective, observational cohort study. Study participants will first be enrolled into the general population main cohort, and some eligible subjects will be invited to participate in a validation study for the consistency of estimated VO₂max. The overall study consists of the establishment of the main cohort and three major research modules: cardiovascular endpoint risk prediction, early warning of exercise-related cardiovascular event risk, and health reminder and behavioral feedback. In addition, a substudy is designed to enroll 300 patients with stable metabolic cardiovascular disease, aiming to verify the consistency between wearable-device-estimated maximal oxygen uptake (VO₂max) and the gold standard of Cardiopulmonary Exercise Testing (CPET), so as to evaluate the applicability and error structure of the device-estimated parameters in clinical populations.
調査の概要
詳細な説明
To establish a prospective cardiopulmonary exercise and active health cohort based on wearable devices, systematically integrate continuous dynamic physiological and behavioral data as well as standardized clinical outcome information, and evaluate the application value of wearable-device-derived metrics in dynamic cardiovascular risk assessment and exercise-related risk identification. Specific objectives are as follows:
- To verify the agreement between wearable-device-estimated VO₂max and CPET measurements.
- To assess the association between continuously monitored wearable metrics and Major Adverse Cardiovascular Events (MACE), and develop a long-term risk prediction model.
- To evaluate the relationship between short-term physiological change features during exercise or physical activity and exercise-related cardiovascular events, and explore methods for dynamic identification of exercise risk.
- To assess the association between health prompts delivered via wearable feedback and individual behavioral and risk changes, and explore the feasibility of active health management.
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100191
- 募集
- Peking University Third Hospital
-
コンタクト：
- YiDa Tang
- 電話番号：+86-10-82265820
- メール：shentao90@bjmu.edu.cn
-
コンタクト：
- Tao Shen
- 電話番号：+86-18201648870
- メール：shentao90@bjmu.edu.cn
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Recruited from volunteers in the general population or health check-up attendees.
説明
Inclusion Criteria:
- Voluntarily participate in the study and sign the informed consent form; agree to continuously wear the wearable device during follow-up; able to complete scheduled follow-up visits
- Enrolled in the main cohort; having stable metabolic cardiovascular diseases (such as hypertension, type 2 diabetes mellitus (T2DM), or dyslipidemia); voluntarily sign the supplementary informed consent for the CPET substudy
Exclusion Criteria:
- Severe mental disorder or cognitive impairment, unable to understand the study content; individuals who cannot or are unsuitable to wear the device
- Presence of contraindications to CPET (e.g., uncontrolled acute coronary syndrome, acute heart failure, severe arrhythmia, etc.); functional impairment that substantially limits exercise capacity; pregnancy or lactation
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：COHORT
- 時間の展望：PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
general healthy population
This group consists of generally healthy individuals without chronic diseases such as hypertension, dyslipidemia, diabetes mellitus, coronary artery disease, and chronic obstructive pulmonary disease (COPD) |
|
Participants with metabolic cardiovascular risk
The exposure factors of this group are hypertension, dyslipidemia, diabetes mellitus, coronary artery disease (CAD), heart failure (HF), and chronic obstructive pulmonary disease (COPD). All of these chronic diseases have been diagnosed in the participants. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Major Adverse Cardiovascular Events (MACE)
時間枠：From the date of baseline enrollment until the date of first MACE or censoring, assessed up to 12 months.
|
Cardiovascular endpoint events: defined as major events meeting the criteria for MACE (including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), extended to other clinically significant adverse cardiovascular events such as heart failure hospitalization, unstable angina visit, and revascularization.All events will be adjudicated by at least two cardiologists based on device recordings, medical documentation and self-reported symptoms. Any disagreements will be resolved by a third-party adjudicator. |
From the date of baseline enrollment until the date of first MACE or censoring, assessed up to 12 months.
|
|
Exercise-Related Cardiovascular Events
時間枠：From the date of baseline enrollment until the date of first exercise-related cardiovascular event or censoring, assessed up to 12 months.
|
Definition of Exercise-Related Cardiovascular Events: Cardiovascular symptoms or events closely induced by exercise that occur during exercise or in the post-exercise recovery period, including but not limited to: (1) Myocardial infarction or angina attack; (2) Tachyarrhythmias: ventricular tachycardia, atrial tachycardia, atrial flutter, atrial fibrillation, paroxysmal supraventricular tachycardia occurring during exercise or recovery; (3) Bradyarrhythmias: newly developed sinus arrest, atrioventricular block, left/right bundle branch block; (4) Abnormal exercise blood pressure: systolic blood pressure ≥210 mmHg (male) or ≥190 mmHg (female) during exercise, abrupt blood pressure drop >10 mmHg with evidence of ischemia during exercise; (5) Syncope, sudden cardiac death, cardiac arrest; (6) Other cardiovascular events resulting in exercise termination. Wearable devices will be used to identify exercise episodes and analyze dynamic physiological characteristics during exercise and recov |
From the date of baseline enrollment until the date of first exercise-related cardiovascular event or censoring, assessed up to 12 months.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- M20260266
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data (IPD) will not be shared with other researchers to protect participant privacy and confidentiality, in compliance with local ethical and data governance requirements.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。